Moderna and Drug Discovery With AI

“The focus of the market and the industry is to make compute infrastructure in its own right a financeable asset class,” says Rich Myers, Morgan Stanley’s global head of structured products and private capital markets. Myers joins Bloomberg Intelligence’s Alexandra Davidov and Ro ...  Show more

Agentic AI and autonomous threats are changing the cyber-resilience landscape and today, data protection and data security have converged. In this episode of the Tech Disruptors podcast, Commvault CEO Sanjay Mirchandani joins Bloomberg Intelligence technology analyst Derek Mogull ...  Show more

Greg Meyers, chief digital and technology officer at Bristol Myers Squibb, explains how AI is transforming pharmaceutical research from hypothesis-driven hunches to data-driven discoveries. Learn how the company is using computational chemistry to engineer breakthrough therapies ...  Show more

Techbio is a field combining data, technology and biology to enhance scientific processes — and AI has the potential to supercharge the biopharmaceutical industry further. In this episode of NVIDIA’s AI Podcast, host Noah Kravitz speaks with Chris Gibson, cofounder and CEO of Rec ...  Show more

Shai Shen-Orr, co-founder and chief scientist at CytoReason and professor at the Technion, talks about the next frontier in healthcare: disease modeling. Shai shares how CytoReason bridges the gap between exploding biological data and actionable insight, powering smarter, faster ...  Show more

Today's guest is Nishtha Jain, Head of Innovation and Digital Technology at Takeda Pharmaceuticals. Nistha returns to the program to discuss the transformative impact of AI across the pharmaceutical value chain. She and Emerj Editorial Director Matthew DeMello explore how AI i ...